Exp Clin Endocrinol Diabetes 2018; 126(02): 85-90
DOI: 10.1055/s-0043-119875
Article
© Georg Thieme Verlag KG Stuttgart · New York

Novel Mutations in the NKX2.1 gene and the PAX8 gene in a Boy with Brain-Lung-Thyroid Syndrome

Pia Hermanns
1   Department of Pediatrics, Johannes Gutenberg University Medical School, Mainz, Germany
,
Małgorzata Kumorowicz-Czoch
2   Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Cracow, Poland
3   Private Pediatrics and Pediatric Endocrinology Practise, Cracow, Poland
,
Helmut Grasberger
4   Department of Medicine, University of Michigan, Ann Arbor, MI, USA
,
Samuel Refetoff
5   Departments of Medicine, Departments of Medicine and Pediatrics, The University of Chicago, Chicago, IL, USA
6   Departments of Medicine and Genetics, The University of Chicago, Chicago, IL, USA
,
Joachim Pohlenz
1   Department of Pediatrics, Johannes Gutenberg University Medical School, Mainz, Germany
› Author Affiliations
Further Information

Publication History

received     11 July 2017
first decision 07 September 2017

accepted      15 September 2017

Publication Date:
27 September 2017 (online)

Abstract

Objective To elucidate the molecular mechanism which causes thyroid dysgenesis (TD) in a boy with brain-lung-thyroid syndrome.

Design, patients, measurements We describe a patient with TD, respiratory disease and cerebral palsy who is heterozygous for mutations in two different genes, the PAX8 (p.E234K) and the NKX2.1 (p.A329GfsX108). In vitro studies were performed to functionally characterize these mutations. Congenital hypothyroidism (CH) was identified by neonatal screening associated with a hypoplastic thyroid gland. Postpartum he developed a brain-lung-thyroid syndrome with severe respiratory failure, symptomatic epilepsy and a considerable psychomotor retardation. The DNA-binding capability and the transcriptional activity of the two mutated transcription factors were investigated in vitro.

Results The NKX2.1 mutation did not show any transcriptional activity and had almost no DNA-binding. The PAX8 mutation was normally located to the nucleus and showed a normal transactivation and a normal binding to the known downstream targets.

Conclusions The molecular defect explaining the phenotype of brain-lung-thyroid syndrome was identified. To what extent the PAX8 mutation contributes to the phenotype needs to be further investigated. We recommend to screen patients with CH and TD for mutations in all known TD candidate genes.

 
  • References

  • 1 Pohlenz J, Deladoey J, Van Vliet G. Developmental abnormalities of the thyroid. In: Weiss RE, Refetoff S. eds Genetic diagnosis of Endocrine Disease. 2. ed London: Elsevier; 2010: 97-100
  • 2 Hermanns P, Grasberger H, Refetoff S. et al. Mutations in the NKX2.5 gene and the PAX8 promoter in a girl with thyroid dysgenesis. J Clin Endocrinol Metab 2011; 96: E977-E981
  • 3 Vilain C, Rydlewski C, Duprez L. et al. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J Clin Endocrinol Metab 2001; 86: 234-238
  • 4 Pohlenz J, Dumitrescu A, Zundel D. et al. Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. J Clin Invest 2002; 109: 469-473
  • 5 Grasberger H, Ringkananont U, Lefrancois P. et al. Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity. Mol Endocrinol 2005; 19: 1779-1791
  • 6 Francis-Lang H, Price M, Polycarpou-Schwarz M. et al. Cell-type-specific expression of the rat thyroperoxidase promoter indicates common mechanisms for thyroid-specific gene expression. Mol Cell Biol 1992; 12: 576-588
  • 7 Zannini M, Francis-Lang H, Plachov D. et al. Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol 1992; 12: 4230-4241
  • 8 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
  • 9 Smith PJ, Zhang C, Wang J. et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006; 15: 2490-2508
  • 10 Cartegni L, Wang J, Zhu Z. et al. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568-3571
  • 11 Monti S, Nicoletti A, Cantasano A. et al. NKX2.1-Related Disorders: A novel mutation with mild clinical presentation. Ital J Pediatr 2015; 41: 45
  • 12 Nettore IC, Cacace V, De Fusco C. et al. The molecular causes of thyroid dysgenesis: A systematic review. J Endocrinol Invest 2013; 36: 654-664
  • 13 Teissier R, Guillot L, Carre A. et al. Multiplex Ligation-dependent Probe Amplification improves the detection rate of NKX2.1 mutations in patients affected by brain-lung-thyroid syndrome. Horm Res Paediatr 2012; 77: 146-151
  • 14 Dale RC, Grattan-Smith P, Nicholson M. et al. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: a single-centre study. Dev Med Child Neurol 2012; 54: 618-623
  • 15 Thorwarth A, Schnittert-Hubener S, Schrumpf P. et al. Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum. J Med Genet 2014; 51: 375-387
  • 16 Pfarr N, Prawitt D, Kirschfink M. et al. Linking C5 deficiency to an exonic splicing enhancer mutation. J Immunol 2005; 174: 4172-4177